
    
      The Primary objective of the study is to assess the safety and tolerability of DBSF (study
      drug) administered to subjects with epilepsy for the treatment of seizures over a minimum
      12-month period.

      Secondary objectives of the study are;

        -  To evaluate the usability of study drug as assessed by the ability of
           caregivers/subjects to administer study drug based on the Instructions for Use (IFU).

        -  To evaluate the Quality of Life of the subjects during the study drug treatment period
           as assessed by age appropriate use of epilepsy scales [Pediatric Quality of Life
           Inventory (PedsQL), Quality of Life in Epilepsy Inventory (QOLIE) 39 and Quality of Life
           in Epilepsy Inventory (QOLIE) 49] over a minimum 12-month period.
    
  